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Objectives: To investigate changes in type 2 diabetes
care indicators over time in Germany.
Methods: Adults aged 45–79 years with type 2 diabetes
were identified from two national health examination
surveys conducted in 1997–1999 (GNHIES98, n=333)
and in 2008–2011 (DEGS1, n=526). We examined
diabetes care indicators including treatment and
preventive targets (glycemic control, blood pressure
(BP), total cholesterol (TC), smoking, weight reduction,
sports activity), self-management and care process
measures (glucose self-monitoring, holding a diabetes
passport, annual foot and eye examination; statin use),
and the presence of diabetes-specific complications
(diabetic nephropathy, retinopathy, neuropathy, diabetic
foot, amputations) and comorbid cardiovascular disease
(CVD) or chronic kidney disease (CKD). We calculated
proportions of persons meeting these care indicators by
survey and examined unadjusted and adjusted changes
between surveys.
Results: Significant improvement (GNHIES98 vs
DEGS1) over time was observed for glycated hemoglobin
(HbA1c) <7.0% (53 mmol/mol) (32.4% vs 65.4%), BP
<130/80 mm Hg (32.0% vs 47.2%), TC <190 mg/dL
(13.5% vs 41.9%), statin use (11.7% vs 35.9%), eye
(51.1% vs 78.4%) and foot (48.0% vs 61.4%)
examination within the past 12 months, diabetes-specific
complications (29.7% vs 21.8%), and CVD (44.5% vs
37.1%). Blood glucose self-monitoring significantly
increased (37.4% vs 62.8%), while holding a diabetes
passport did not change. Current smoking did not
change and obesity rose, although sports activity
significantly increased over time. Proportions of adults
achieving combination goals of HbA1c, BP, TC, and
smoking cessation were low in both surveys in spite of
significant improvement.
Conclusions: In Germany, the quality of diabetes care
improved over time. There is much room for
improvement, in particular regarding preventive goals
and diabetes self-management.
INTRODUCTION
Diabetes represents a major threat to public
health in many countries of the world.
International health organizations have
emphasized the necessity for national plans
to improve diabetes prevention and quality
of care, but continuous monitoring of quality
of care indicators at the population level
remains a challenge for many countries.1 2
Individualized glycemic control and multifac-
torial risk reduction are the cornerstones of
high-quality diabetes care.3–6 Evidence-based
guidelines for the management of diabetes
recommend lowering glycated hemoglobin
(HbA1c) levels to <7.0% (53 mmol/mol) for
most people with diabetes, but outline that
certain individuals may benefit from more
stringent (6.0–6.5%; 42–48 mmol/mol) and
less stringent (7.5–8.0%, 58–64 mmol/mol)
glycemic control.3–6 Optimal individualized
diabetes management includes controlling
cardiovascular risk factors (eg, hypertension
and dyslipidemia), preventive strategies such
as annual eye and foot examinations, and
lifestyle modifications, in particular smoking
cessation, weight reduction and increasing
moderate physical activity to at least 150
min/week.3 6
In Germany, about six million adults are
estimated to have diabetes.7 In an effort to
Key messages
▪ Quality of care for adults with type 2 diabetes
substantially improved in Germany between
1997–1999 and 2008–2011.
▪ Improvements in quality of care for adults with
type 2 diabetes in Germany were most pro-
nounced for process and intermediate outcome
measures, such as annual eye examinations and
glycemic control.
▪ Quality of care for adults with type 2 diabetes in
Germany still falls short of evidence-based
guideline recommendations, in particular with
regard to combined therapeutic goal achieve-
ment, behavioral risk factor control, and patient
self-management.
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improve diabetes care, type 2 diabetes disease manage-
ment programs (DMPs) were initiated nationally in 2003.8
These programs incorporated prevention and treatment
goals and strategies recommended in international and
national guidelines. Tracking quality of care indicators at
the population level is essential to help understand
successes and failures in prevention and treatment goals
for diabetes care and to direct quality improvement initia-
tives and health policy. To date, no studies have compre-
hensively investigated the quality of diabetes care over
time at the national level. Previous studies of changes over
time have been limited to regional population-based
surveys and practice-based studies or analyses of data from
different statutory sickness funds.9–12
In this study, we examine changes in quality of care
indicators for adults in Germany with type 2 diabetes
using nationally representative data collected in 1997–
1999 and 2008–2011. Diabetes care indicators included
therapeutic and preventive goals such as glycemic, blood
pressure (BP) and lipid control, diabetes self-
management and care process measures, and diabetes
comorbidities and complications.
RESEARCH DESIGN AND METHODS
Study design and participants
We analyzed data from two national health interview and
examination surveys for adults in Germany conducted in
1997–1999 and 2008–2011 by the Robert Koch Institute,
the national public health institute for disease control and
prevention in Germany. In both surveys, a two-stage prob-
ability cluster sampling procedure was applied to ensure
that the survey sample was representative of the resident
population in Germany aged 18–79 years. Details of the
study design, sampling strategy, and protocol have been
previously published.13 14 Briefly, in the German National
Health Interview and Examination Survey in 1997–1999
(GNHIES98), a sample of 120 German municipalities, rep-
resentative of municipality sizes and structures in
Germany, were selected. In the second stage, age-stratified
and sex-stratified random samples of adults aged 18–
79 years were drawn from local population registries. The
final GNHIES98 sample included 7124 adults (response
rate was 61.4%) with complete interview and examination
data.13 The National Health Interview and Examination
Survey for Adults in Germany 2008–2011 (DEGS1) used
the same sampling methods as GNHIES98 but included
60 additional municipalities. The DEGS1 sample 18–
79 years of age comprised 7987 persons, including 4192
persons who were newly recruited in DEGS1 and 3795
persons who had already participated in GNHIES98. The
response rate was 42% for first-time survey participants
and 64% for GNHIES98 re-participants.14 15 Among
DEGS1 study participants 18–79 years, a total of 7115
persons attended one of the study centers and completed
both the interview and examination.14 15
The present analysis is confined to participants with
known diabetes. We selected those who: (1) answered
‘Yes’ to the question “Have you ever been diagnosed with
diabetes by a doctor?” or (2) used antidiabetic medica-
tions including insulin and/or oral agents within the
past 7 days. Overall, we identified 374 adults with known
diabetes from the 7124 participants in GNHIES98 and
591 adults with known diabetes from the 7115 partici-
pants with complete interview and examination data in
DEGS1. No question on the type of diabetes was
included in the surveys.7 In order to focus on type 2 dia-
betes, we confined this analysis to persons with known
diabetes 45–79 years of age, excluding 101 (n=38 in
GNHIES98; n=63 in DEGS1) persons with diabetes
younger than 45 years at the time of the survey.
Furthermore, we excluded another five persons with
known diabetes (n=3 in GNHIES98; n=2 in DEGS1) who
were likely to have type 1 diabetes as they fulfilled a com-
bination of the following criteria: age at diagnosis of dia-
betes <30 years, insulin prescribed at initial diagnosis
and currently using insulin.7 The final study population
comprised 333 adults in GNHIES98 and 526 adults in
DEGS1 aged 45–79 years with known diabetes who are
described as having type 2 diabetes (table 1).
Both surveys conform to the principles outlined in the
Declaration of Helsinki and the German Federal Data
Protection Act. Study protocols were approved by the
Federal and State Commissioners for Data Protection
and Freedom of Information. DEGS1 was approved by
the Charité Universitätsmedizin Berlin ethics committee
in September 2008 (number EA2/047/08). All partici-
pants provided written informed consent prior to the
interview and examination.
Data collection and definition of study characteristics
Data collection methods in DEGS1 were largely compar-
able to those used in GNHIES98 and have been previously
described in detail.14 Standardized self-administered ques-
tionnaires, physician-administered computer-assisted per-
sonal interviews (CAPI), and physiological measurements
and tests were used to collect information on sociodemo-
graphic characteristics (age, sex, region of residence, edu-
cational attainment), health-related behaviors (current
tobacco use and sports activities in the past 3 months), self-
reported physician-diagnosed health conditions, and
anthropometric (body weight and height) and biochem-
ical measures.13 14
Individuals with diabetes were asked about their age at
first diagnosis, current treatment and treatment at the
time of diagnosis, diabetes-specific complications (includ-
ing diabetic nephropathy, diabetic retinopathy, diabetic
neuropathy, diabetic foot and diabetes-related amputa-
tion), eye and foot examinations in the past 12 months,
self-monitoring of blood glucose, holding a diabetes pass-
port (a national patient-held record of their care), and
whether they had ever participated in a diabetes education
program. We defined treatment categories as no treatment
at all, dietary treatment only, and pharmaceutical treat-
ment (oral antidiabetic agents and/or insulin). Diabetes
duration was computed by subtracting the age at diagnosis
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from the person’s current age and grouped as ‘<5’, ‘5–14’
and ‘≥15’ years.
Participants were asked to bring the original contain-
ers of all medication used during the past 7 days to the
examination site. This permitted automated recording
of unique product identifiers and drug coding accord-
ing to the WHO “Anatomical Therapeutic Chemical”
(ATC) classification system.16 A medication with an ATC
code A10A and A10B was considered as ‘insulin’ and
‘oral agent’, respectively.
Body mass index (BMI) was calculated as the ratio of
body weight (kg) and body height (m) squared with
participants wearing light clothing (GNHIES98) or
underwear (DEGS1) and shoes removed.17 Three stan-
dardized BP measurements were taken at 3 minute inter-
vals in upright sitting with a standard mercury
sphygmomanometer in GNHIES98 and an oscillometric
device (Datascope Accutorr Plus) in DEGS1. One of
three cuff sizes was selected according to the right
mid-arm circumference. GNHIES98 measurements were
calibrated for comparison with DEGS1 measurements in
order to account for device and cuff differences.18
Random venous blood samples were obtained between
8:00 and 20:00 with participants in the seated position.
Full details of specimen handling and laboratory ana-
lyses for HbA1c, total cholesterol (TC), and creatinine
are provided in the online supplementary appendix.
Educational attainment was classified using the inter-
national Comparative Analysis of Social Mobility in
Industrial Nations (CASMIN) scale and grouped as
‘primary’, ‘middle’, and ‘high’.19 Municipality size was
classified as rural town (<5000 inhabitants) and small
(5000–<20 000), medium-sized (20 000–<100 000), and
large (100 000 inhabitants or more) cities, based on
population density according to an established German
classification system.14 Regions of residence were grouped
into five commonly described geographical areas: north-
west (federal states: Bremen, Hamburg, Niedersachsen,
and Schleswig-Holstein); northeast (Berlin,
Brandenburg, and Mecklenburg-Vorpommern); central
west (Hessen, Nordrhein-Westfalen, Rheinland-Pfalz, and
Saarland); central east (Sachsen, Sachsen-Anhalt, and
Thüringen); south (Baden-Württemberg and Bayern).
Smoking status was categorized as never-smoking, former
smoking, and current smoking. The World Health
Organization (WHO)-recommended criteria were
applied to define normal weight (BMI <25.00 kg/m2),
pre-obese (BMI 25.00–29.99 kg/m2), obese class I (BMI
≥30.00–34.99 kg/m2), and obese classes II and III (BMI
≥35).20 Sports activity was assessed by five categories (no
sports, <1 hour/week, regularly 1–2 hours/week, regu-
larly 2–4 hours/week, regularly >4 hours/week). This
information was aggregated into three categories (no
sports, <2 hours/week, ≥2 hours/week). Since the
number of people with diabetes engaging in ≥2 hours/
week of sports activity in 1998 was small (n=20), we cate-
gorized this variable as no sports versus any sports activity
for the analysis.
Diabetes care indicators
Indicators were based on clinical guidelines for recom-
mended care3–6 including achievement of treatment and
preventive goals (control of HbA1c, BP, and TC), patient
self-management (glucose self-monitoring, holding a dia-
betes passport), and care process measures (eye and foot
examination within the past 12 months, statin use, angio-
tensin converting enzyme (ACE) inhibitor or angiotensin
receptor blocker (ARB) use). We also assessed a number
of additional preventive targets, including the proportion
of persons with type 2 diabetes who were: (1) non-obese
(BMI <30 kg/m2); (2) not currently smoking; and (3)
engaging in any sports activities.
We considered stringent and less stringent cut-offs for
glycemic control ranging from HbA1c <6.5% (48 mmol/
mol) to <8.0% (64 mmol/mol) as well as for BP (<130/
80 and <140/90 mm Hg) and TC (<190 and <240 mg/
dL). Individualized glycemic control takes into consider-
ation the persons’ age and presence of complications.4
Consistent with previous studies,21 we defined the indivi-
dualized HbA1c target as <8.0% (64 mmol/mol) for
adults with diabetes-specific complications or comorbid
cardiovascular diseases (CVD), <7.0% (53 mmol/mol)
for adults 45–64 years, and <7.5% (58 mmol/mol) for
adults 65–79 years without these problems. Furthermore,
we defined combined goals of diabetes care as previ-
ously described,21 with the exception of using total
instead of low-density lipoprotein (LDL) cholesterol:
goal 1: HbA1c <7.0% (53 mmol/mol), BP <130/
80 mm Hg, TC <190 mg/dL, and not currently smoking;
goal 2: HbA1c <7.5% (58 mmol/mol), BP <140/
90 mm Hg, TC <240 mg/dL, and not currently smoking.
The study population was characterized according to
the presence of any self-reported diabetes-specific com-
plication (yes/no) and diabetes-related comorbidities,
including self-reported CVD and chronic kidney disease
(CKD). Adults reporting a history of physician-diagnosed
heart failure, stroke, myocardial infarction, and other
coronary heart disease were classified as having CVD.
For those without CVD, we calculated the 10-year UK
Prospective Diabetes Study (UKPDS) CVD risk in per
cent using the original version which considers patients’
age, sex, HbA1c, BP, TC, smoking status, and other risk
factors.22 CKD was defined according to the
International Society of Nephrology23 based on an esti-
mated glomerular filtration rate (eGFR) <60 mL/min/
1.73 m2 or the presence of moderate to severe albumin-
uria. eGFR values were calculated by the CKD-EPI
formula24 using measured serum creatinine levels. In
German health examination surveys, microalbuminuria
was assessed semi-quantitatively using Micral-Test
albumin dipstick testing and a cut-off of >50 mg/L was
used to define moderate to severe microalbuminuria
based on previous evidence on test performance.25
Statistical analysis
SAS V.9.4 survey procedures for complex samples (SAS
Institute Inc, Cary, North Carolina, USA) were used for
BMJ Open Diabetes Research and Care 2015;3:e000135. doi:10.1136/bmjdrc-2015-000135 3
Epidemiology/health services research
statistical analyses. Comparisons between the two surveys
are based on weighted estimates standardized to the
population of 31 December 2010. Survey weights were
computed as previously described14 15 to account for
deviations between the sample and the structure of the
general population regarding age, sex, region, national-
ity, and education.7 14 15 In DEGS1, weighting factors
additionally included the probability of re-participation
in DEGS1 as derived from logistic regression models.15
Descriptive statistics were used to examine character-
istics of adults with type 2 diabetes and diabetes care
indicators. Point estimates (means and proportions) and
95% CIs were reported. Rao-Scott corrected Pearson
tests for categorical variables and general linear models
for continuous variables were used. For each diabetes
care indicator, we calculated the absolute changes in
proportions (and 95% CI) between surveys, both
unadjusted and adjusted for sex, age group, region,
community size, educational level, and duration of dia-
betes. The adjusted changes in proportions were derived
from the predictive margins calculated from a logistic
regression model.26 First-order interactions between the
survey year variable and each covariates were tested sep-
arately and interaction terms included in the model if
p<0.1. The predictive margins were calculated as the
adjusted probabilities predicted by the model, averaged
over all participants in the model and assuming that the
covariate distribution in GNHIES98 and DEGS1 were
identical. The SEs and correlation of the predictive
margins were approximated by the SAS LSMEANS state-
ment and used in the calculation of the 95% CI for the
adjusted change in proportions. Kernel density estima-
tion was applied to compare weighted HbA1c distribu-
tions among persons with diabetes between surveys.
For questions related to medical history, eye and foot
examinations, and diabetes complications, an additional
‘don’t know’ answering category was included in DEGS1,
whereas in GNHIES98 only ‘yes’ and ‘no’ options were
available. We therefore treated persons answering ‘don’t
know’ in DEGS1 as missing in analyses, but also conducted
sensitivity analyses coding these answers as ‘no’ to ensure
consistency of results. Since the results were similar, only
results based on coding ‘don’t’ know’ answers as missing
are presented. For each variable, weighted proportion and
unweighted n depict the number of participants with com-
plete information. The number of persons with missing
values was explicitly stated for each variable. Persons with
missing values were excluded from the analyses, with pair-
wise deletion for descriptive and listwise deletion for multi-
variable analyses. Statistical significance was defined at
p<0.05 based on two-sided tests.
RESULTS
Persons with type 2 diabetes in DEGS1 had higher edu-
cational attainment, more frequently engaged in sports
activities, were more often ex-smokers, and had higher
BMI levels than those in GNHIES98 (table 1). Between
the 1997–1999 and 2008–2011 surveys, mean age at diag-
nosis declined from 56.3 to 54.6 years (p=0.07) and
mean years of diabetes duration increased significantly
from 9.2 to 11.3 years (p=0.012). In sex-specific analyses,
these differences were statistically significant among
women (mean age at diagnosis: 57.3 vs 54.1 years,
p=0.041; diabetes duration: 9.8 vs 12.4 years, p=0.045),
but not among men (mean age at diagnosis: 55.4 vs
55.0 years, p=0.757; diabetes duration: 8.6 vs 10.3 years,
p=0.091).
Figure 1 shows the HbA1c distribution among adults
with type 2 diabetes in the two surveys. The HbA1c dis-
tribution in DEGS1 has shifted to the left and shows
considerably lower variability compared to GNHIES98.
Significantly more persons with type 2 diabetes
achieved guideline-recommended stringent and less
stringent targets for HbA1c, BP, and TC as well as the
individualized HbA1c target and the combined treat-
ment goals in 2008–2011 compared to the 1997–1999
survey period (table 2). The proportion of persons with
diabetes reporting any sports activity significantly
increased between the two surveys, while the proportion
of current non-smokers remained unchanged and the
proportion of non-obese persons decreased over time.
Improvements in care processes over time were reflected
by increasing ACE inhibitor/ARB and statin use, and
increasing proportions of persons reporting eye or foot
examinations within the past 12 months. Proportions of
adults with type 2 diabetes reporting glucose self-
monitoring increased over time, but holding a diabetes
passport did not significantly differ between the two
surveys. A significant decrease between the surveys was
found in the proportion of adults reporting diabetes-
specific complications or comorbid CVD, but not in the
proportion of adults with comorbid CKD (table 2).
Among adults without a history of CVD, the 10-year
UKPDS risk score declined significantly over time.
DISCUSSION
Community-dwelling adults aged 45–79 years with type 2
diabetes in Germany showed consistent improvements in
diabetes care between the survey periods 1997–1999 and
2008–2011. Improvement was seen for treatment targets
(HbA1c, BP, serum lipids), statin and ACE inhibitor/
ARB use. Self-monitoring of blood glucose levels and
uptake of annual eye or foot examinations also
improved. Furthermore, the proportion of adults with
type 2 diabetes reporting any diabetes-specific complica-
tions and comorbid CVD decreased significantly.
However, there was no significant decrease in the pro-
portions of adults with diabetes having evidence of CKD.
The proportion of people with diabetes and obesity rose
over this period and the proportion of those currently
smoking was unchanged. Although overall engagement
in sports activity significantly improved over time, less
than one in five adults in 2008–2011 reported perform-
ing more than 2 hours of sports activity per week; this is
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well below the guideline recommended levels of physical
activity (>150 min/week) for adults with diabetes.3 6
There may be several reasons for the observed
improvements in some, albeit not all, diabetes care
indicators in Germany. First, there was the introduction
of a national type 2 DMP in 2003, between these national
health examination surveys 1997–1999 and 2008–2011.8
DMP enrollment comprises regular check-up visits and
Table 1 Characteristics of adults aged 45–79 years with type 2 diabetes in German national health interview and examination surveys
1997–1999 (GNHIES98) and 2008–2011 (DEGS1)
GNHIES98 (1997–1999) (N=333) DEGS1 (2008–2011) (N=526)
p Valuen Per cent * 95% CI* n Per cent* 95% CI*
Categorical variables (in %)
Sex
Men 160 48.7 42.8 to 54.6 298 53.1 47.3 to 58.8 0.221
Women 173 51.3 45.4 to 57.2 228 46.9 41.2 to 52.7
Age group, years
45–64 171 43.2 36.8 to 49.8 184 37.6 32.1 to 43.4 0.229
65–79 162 56.8 50.2 to 63.2 342 62.4 56.6 to 67.9
Municipality size
Rural town 84 19.3 12.3 to 28.9 111 18.1 11.8 to 26.8 0.628
Small city 75 20.8 13.1 to 31.3 128 26.1 18.6 to 35.2
Medium-sized city 89 32.4 22.6 to 43.9 150 30.0 22.2 to 39.3
Large city 85 27.6 18.7 to 38.6 137 25.8 18.4 to 34.8
Region†
North-west 27 11.6 6.4 to 20.0 62 15.4 9.7 to 23.5 0.090
Central west 81 30.2 20.9 to 41.4 161 37.9 29.0 to 47.7
North-east 57 14.5 7.8 to 25.2 73 10.3 6.3 to 16.3
Central east 99 15.3 9.9 to 22.9 133 14.4 9.4 to 21.4
South 69 28.5 19.1 to 40.3 97 22.1 15.1 to 31.1
Educational level‡
Primary 234 78.6 72.3 to 83.8 280 62.3 56.4 to 67.8 <0.001
Middle 58 14.1 10.4 to 18.7 162 28.2 23.3 to 33.7
High 25 7.3 4.1 to 12.6 81 9.5 7.0 to 12.8
Body mass index, kg/m2
<25 44 12.9 9.1 to 18.0 55 11.7 9.0 to 14.9 0.001
25–29.99 149 48.3 42.6 to 54.0 184 41.1 36.9 to 45.4
30–34.99 93 25.9 20.4 to 32.2 176 30.0 26.0 to 34.4
≥35 42 12.9 9.4 to 17.4 107 17.2 14.6 to 20.2
Smoking status
Smoker 60 19.5 14.5 to 25.8 85 18.2 14.3 to 22.9 0.033
Ex-smoker 89 27.5 22.2 to 33.6 220 38.0 33.1 to 43.2
Non-smoker 170 52.9 46.3 to 59.5 217 43.8 38.4 to 49.3
Sports activity, hours/week
0 (no sports) 231 76.1 69.0 to 82.0 231 47.7 42.0 to 53.5 <0.001
0–2 66 17.3 12.0 to 24.4 171 34.3 29.4 to 39.5
≥2 20 6.6 4.0 to 10.7 91 18.0 13.9 to 23.1
Diabetes treatment pattern
No treatment at all 42 13.6 9.7 to 18.8 75 17.3 12.7 to 23.1 0.068
Diet only 51 15.6 11.9 to 20.2 54 9.3 6.8 to 12.8
Insulin only (with or without diet) 33 10.8 7.1 to 16.0 56 11.6 8.5 to 15.7
Oral agents only (with or without diet) 166 51.9 45.1 to 58.7 262 48.2 42.6 to 53.8
Both insulin and oral agents (with or without diet) 30 8.0 5.3 to 12.1 67 13.6 10.0 to 18.2
Diabetes duration, years
<5 125 37.3 30.4 to 44.7 160 29.7 25.1 to 34.8 0.174
5–14 126 36.5 30.5 to 43.1 210 41.9 36.2 to 47.8
≥15 77 26.2 20.9 to 32.3 140 28.4 23.5 to 33.8
Continuous variables (mean) n Mean* 95% CI* n Mean* 95% CI*
Age, years 333 65.5 64.4 to 66.6 526 66.0 65.0 to 67.0 0.549
Age at diagnosis of diabetes, years 328 56.3 54.9 to 57.7 510 54.6 53.1 to 56.0 0.070
Diabetes duration, years 328 9.2 8.1 to 10.3 510 11.3 10.0 to 12.6 0.012
Denominators vary due to the number of persons with missing values. Missing values (GNHIES98, DEGS1): educational level (n=16, n=3),
body mass index (n=5, n=4), smoking status (n=14, n=4), sports (n=16, n=33), diabetes treatment pattern (n=11, n=12), age at the initial
diagnosis of diabetes and diabetes duration (n=5, n=16).
*Weighted and standardized to the population of 31 December 2010.
†Region: Northwest (federal states: Bremen, Hamburg, Niedersachsen, and Schleswig-Holstein); northeast (Berlin, Brandenburg, and
Mecklenburg-Vorpommern); central west (Hessen, Nordrhein-Westfalen, Rheinland-Pfalz, and Saarland); central east (Sachsen,
Sachsen-Anhalt, and Thüringen); south (Baden-Württemberg and Bayern).
‡Educational attainment was classified using the international Comparative Analysis of Social Mobility in Industrial Nations (CASMIN) scale.
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aims to promote diabetes education, adherence to treat-
ment goals, and self-management.8 27 28 Physicians are
contracted under the provision of structural quality
requirements and reimbursement is provided with a
focus on intermediate outcome measures, such as
HbA1c measures. This key national policy change and
the introduction of financial incentives for physicians to
improve diabetes care are likely to have contributed to
the improvements in glycemic control and statin use as
observed in the present study. However, we found mixed
results regarding diabetes self-management with
improvements in glucose self-monitoring but not
keeping a diabetes passport. Second, evidence-based
national diabetes management and treatment guidelines
have been periodically updated between the survey
periods and are integral to DMP contracts.6 Third, guide-
line recommendations regarding the diagnostic criteria
for type 2 diabetes based on fasting glucose changed in
1998, that is, toward the end of GNHIES98.29 Together,
these changes in between survey periods might have con-
tributed to an earlier diagnosis of type 2 diabetes. We
found that the age at diagnosis of diabetes was on
average 1.7 years earlier in DEGS1 than in GNHIES98.
Survey participants detected at an earlier phase of the
disease course may have more favorable intermediate
outcome measures (HbA1c, BP, cholesterol), and are less
likely to have diabetes-specific complications compared
with those at a more advanced phase of disease. In sex-
specific analyses, a significant difference regarding an
earlier age at diagnosis in DEGS1 vs GNHIES98 was con-
fined to women, which may reflect sex differences in
care (eg, diagnosis of gestational diabetes) and/or
healthcare services utilization.
In Germany, previous studies of changes in diabetes
quality of care indicators over time have been confined
to regional population-based studies11 or studies among
primary care patients.30 In repeated population surveys
conducted in southern Germany, recommended eye or
foot examinations among adults with type 2 diabetes sig-
nificantly increased between 1999–2001 and 2006–2008
(60.5% vs 71.3% and 37.5% vs 55.1% respectively), as
did the use of lipid-lowering drugs (18.0% vs 37.9%),
and the percentage of adults with diabetes achieving BP
targets of <140/90 mm Hg (43.6% vs 70.5%).11 These
findings are largely consistent with our results. However,
unlike our findings, the proportions of persons with dia-
betes achieving HbA1c targets of <7.0% (53 mmol/mol)
and those with a BMI ≤30 kg/m2 remained unchanged
in the previous study.11 In a study based on data from
110 primary care practices across Germany, the propor-
tion of patients with diabetes achieving HbA1c <6.5%
(48 mmol/mol) increased from 31% in 1998 to 36% in
2005, while the percentage of patients with HbA1c
≥9.0% (75 mmol/mol) was halved from about 20% to
10% over this time period,30 roughly comparable to our
findings from 23.5% in 1997–1999 to 4.6% in 2008–2011
(table 2). Our findings of improvements in diabetes-
related complications among our sample are consistent
with a variety of studies using various data sources over
the past decade in Germany (eg, regional disease regis-
tries or hospital discharge data, selected sickness funds)
reporting improvements in amputation rates, the inci-
dence of blindness, and cardiovascular risk reduction,
particularly among women.31–33
Time trend analyses of diabetes care indicators based
on repeated national health surveys have been con-
ducted in the USA. Results from these studies have con-
sistently demonstrated significant improvements in the
control of HbA1c, BP, and lipids among adults with
diabetes, although absolute changes over the past
decade were generally smaller than those observed in
the present study.21 34–37 Between the 1999–2002 and
2007–2010 NHANES survey waves, the proportion of
adults with diabetes achieving HbA1c <7.0% (53 mmol/
mol), BP <130/80 mm Hg, and LDL-cholesterol
<100 mg/dL increased significantly by 7.9, 11.7, and
Figure 1 Density distribution of
glycated hemoglobin (HbA1c)
among adults aged 45–79 years
with type 2 diabetes. German
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Table 2 Absolute change (95% CI) in the prevalence of diabetes care indicators among adults with type 2 diabetes over time, German national health interview and examination surveys 1997–1999 and
2008–2011
GNHIES98 (1997–1999) (N=333) DEGS1 (2008–2011) (N=526) Absolute change (DEGS1-GNHIES98)
Unadjusted Adjusted*
n Per cent† 95% CI† n Per cent† 95% CI† Per cent† 95% CI† Per cent† 95% CI†
Preventive and therapeutic goals
HbA1c
<6.5% (48 mmol/mol) 78 22.9 17.8 to 28.9 256 48.8 42.7 to 55.0 25.9 17.4 to 34.4 27.5 18.8 to 36.3
<7.0% (53 mmol/mol) 105 32.4 26.8 to 38.7 346 65.4 59.6 to 70.7 32.9 24.9 to 41.0 34.8 26.1 to 43.5
<7.5% (58 mmol/mol) 148 45.2 38.8 to 51.7 406 79.1 74.6 to 83.0 33.9 26.1 to 41.8 36.2 26.5 to 45.9
<8.0% (64 mmol/mol) 179 55.3 49.2 to 61.2 451 86.9 82.8 to 90.1 31.6 24.6 to 38.5 35.7 27.0 to 44.4
≥9.0% (75 mmol/mol) 72 23.5 18.0 to 30.1 23 4.6 2.8 to 7.6 −18.9 −25.4 to −12.3 −23.3 −30.3 to −16.3
Individualized HbA1c target 156 49.3 43.2 to 55.5 379 80.7 75.5 to 85.0 31.3 23.2 to 39.5 33.9 25.0 to 42.8
Total cholesterol (mg/dL)
<190 37 13.5 9.0 to 19.9 224 41.9 36.6 to 47.3 28.3 20.0 to 36.7 25.7 16.2 to 35.1
<240 154 52.0 44.9 to 59.0 442 85.3 80.6 to 89.0 33.3 25.0 to 41.6 32.2 23.9 to 40.6
Blood pressure (mm Hg)
<130/80 103 32.0 26.2 to 38.4 240 47.2 41.2 to 53.3 15.2 6.4 to 24.0 20.3 11.5 to 29.1
<140/90 181 56.3 49.5 to 62.9 364 69.6 63.8 to 74.8 13.3 4.6 to 21.9 18.2 8.9 to 27.4
Body mass index <30 kg/m2 193 61.2 55.4 to 66.7 239 45.6 40.0 to 51.4 −15.6 −23.5 to −7.7 −16.6 −26.0 to −7.3
Currently not smoking 259 80.5 74.2 to 85.5 437 81.8 77.1 to 85.7 1.4 −6.0 to 8.7 −1.4 −8.1 to 5.2
Engaging in any sports activity 86 23.9 18.0 to 31.0 262 52.3 46.5 to 58.0 28.4 19.1 to 37.7 28.5 18.0 to 39.0
Combination goal 1 5 1.7 0.5 to 5.1 60 11.4 8.4 to 15.4 9.8 5.8 to 13.7 9.5 6.0 to 13.0
Combination goal 2 31 10.9 7.2 to 16.0 201 39.6 34.0 to 45.4 28.7 21.6 to 35.8 31.1 24.3 to 37.8
Patient self-management
Self-monitoring of blood glucose 119 37.4 30.8 to 44.6 318 62.8 57.3 to 68.0 25.3 16.8 to 33.9 24.0 15.6 to 32.5
Holding a diabetes passport 172 46.9 39.8 to 54.2 287 54.2 48.4 to 60.0 7.3 −1.2 to 15.9 2.4 −7.1 to 11.8
Care processes
Last eye examination ≤12 months 170 51.1 44.8 to 57.3 389 78.4 73.6 to 82.6 27.3 19.3 to 35.4 22.2 12.8 to 31.5
Last foot examination ≤12 months 151 48.0 41.2 to 54.9 303 61.4 55.3 to 67.1 13.4 4.0 to 22.8 10.0 0.6 to 19.3
Any ACE inhibitor or ARB 119 34.7 28.6 to 41.3 335 60.7 54.6 to 66.4 26.0 17.2 to 34.7 22.7 12.7 to 32.6
Any lipid-lowering medication 62 18.2 13.8 to 23.7 216 39.6 33.8 to 45.7 21.4 13.7 to 29.0 18.8 10.6 to 27.0
Statin use 40 11.7 8.4 to 16.1 195 35.9 30.3 to 41.9 24.2 17.6 to 30.9 22.5 15.3 to 29.7
Complications/comorbidities/CVD risk
Any diabetes-specific complication 93 29.7 23.9 to 36.2 107 21.8 17.9 to 26.3 −7.9 −15.6 to −0.2 −9.7 −17.0 to −2.0
Comorbid CVD 138 44.5 38.0 to 51.3 184 37.1 31.3 to 43.3 −7.4 −16.7 to 1.8 −10.3 −21.0 to 0.6
Comorbid chronic kidney disease 120 44.8 37.9 to 51.8 226 40.3 34.8 to 46.0 −4.5 −13.1 to 4.2 −9.1 −20.0 to 1.3
UKPDS risk (in %) for persons without CVD 172 21.0 18.9 to 23.2 303 15.9 14.5 to 17.3 −5.2 −7.7 to −2.7 −6.1 −8.2 to −4.1
Results for absolute changes in bold print denote statistically significant differences based on p values derived from descriptive analyses (unadjusted change) or logistic regression models
(adjusted change).
Individualized HbA1c target: <8.0% (64 mmol/mol) for adults with diabetes-specific complications or comorbid CVD, <7.0% (53 mmol/mol) for adults 45–64 years, and <7.5% (58 mmol/mol) for
adults 65–79 years without these problems. Combination goal 1: HbA1c <7.0% (53 mmol/mol) and blood pressure <130/80 mm Hg and total cholesterol <190 mg/dL and not currently smoking;
Combination goal 2: HbA1c <7.5% (58 mmol/mol) and blood pressure <140/90 mm Hg and total cholesterol <240 mg/dL and not currently smoking.
Denominators vary due to the number of persons with missing values. Missing values (GNHIES98, DEGS1): HbA1c (n=26, n=8), individualized HbA1c target (n=28, n=63), total cholesterol
(n=24, n=6), blood pressure (n=1, n=2), combination goal 1 and goal 2 (n=41, n=15), self-monitoring blood glucose (n=5, n=12), holding a diabetes passport (n=5, n=12), eye examination (n=5,
n=24), foot examination (n=5, n=34), any lipid-lowering medication and statin use (n=0, n=1), diabetes-specific complication (n=5, n=72), comorbid CVD (n=0, n=25), comorbid chronic kidney
disease (n=56, n=7), UKPDS risk (n=23, n=14).
*Adjusted for sex, age group (45–64, 65–79 years), region (northwest, central west, northeast, central east, south), community size (rural town, small, middle-sized, and large cities), educational
level (primary, middle, high), duration of diabetes (<5, 5–14, ≥15 years) and significant first-order interactions (p<0.100) as shown in the online supplementary table 1A.
†Weighted and standardized to the population of 31 December 2010.




































20.8 percentage points, respectively,21 as compared
to 32.9, 15.2, and 28.3 percentage points for HbA1c
<7.0% (53 mmol/mol), BP <130/80 mm Hg, and TC
<190 mg/dL in the present analysis. Unfortunately, some
indicators are not directly comparable between
NHANES and the German national health surveys.
Unlike NHANES, the present study used TC instead of
LDL-cholesterol, as the German surveys did not recruit a
random subsample of adults who observed overnight
fasting for at least 8 h.13 14 Alongside the significantly
improved profiles of HbA1c, BP measures, and choles-
terol, use of antidiabetic medication, antihypertensive
agents, and lipid-lowering drugs significantly increased
over time as observed in our study and previously in US
population studies.34–37 We found that 8.0% of adults
with diabetes in GNHIES98 and 13.6% in DEGS1 used a
combination of insulin and oral agents, similar to 9.8%
and 13.9% of adults with diabetes in the 1999–2004 and
2005–2010 NHANES waves.34 Over the same time
period, lipid-lowering drug use increased from 18.2% to
39.6% among adults with diabetes in Germany as shown
in this analysis, similar to increases in NHANES partici-
pants from 19.5% in 1999–2000 to 42.2% in 2007–
2008.38 Consistent with our findings, analyses of data
from the US Behavioral Risk Factor Surveillance System
(BRFSS) survey waves 2000 and 2008 showed significant
improvements with respect to the proportion of adults
with diabetes reporting annual foot examinations and
glucose self-monitoring.21 Unlike our findings, self-
reported eye examination among adults with diabetes in
BRFSS showed no further improvement over time,21 but
baseline coverage for this indicator already achieved a
much higher level in the USA in the 2000 survey with
75.1% compared to 51.1% in GNHIES98. Data from offi-
cial health statistics (National Hospital Discharge Survey,
US Renal Data System, National Vital Statistics System)
have been systematically used to analyze trends in rates
of diabetes-related complications in the USA and
provide clear evidence for a decline in myocardial
infarction, and death from hyperglycemic crisis, stroke,
and amputation among people with diabetes between
1990 to 2010.39 This remains a major goal for diabetes
surveillance in Germany, where evidence on long-term
outcomes is limited so far.8
Despite significant improvements in diabetes care
observed over the past decade, the current level of care
in Germany as in other countries such as the USA,21 34–37
Canada,40 and Spain41 falls short of guideline recommen-
dations. Similar to these studies,21 40 41 the results of the
present analysis based on data from German national
health surveys show that about two-thirds of persons with
type 2 diabetes reached the target of HbA1c <7.0%
(53 mmol/mol), and only 11.4% of patients with dia-
betes achieved stringent targets in HbA1c, TC, BP, and
smoking combined. There was little change in the preva-
lence of current smokers among adults with diabetes in
our study similar to US diabetes population studies.21 37
Rising obesity among diabetes populations is a concern
for numerous countries37 and highlights population chal-
lenges of guideline-recommended weight reduction.
Weight gain among persons with diabetes has been
observed in relation to treatment with insulin and certain
oral antidiabetic agents.42 43 Further insight from longitu-
dinal studies is needed to assess the effect of weight gain
on long-term cardiovascular risk and mortality.42 43
The major strength of this analysis is that it provides
comprehensive data on changes in diabetes quality of
care indicators over time including the time period
before (1997–1999) and after (2008–2011) the introduc-
tion of DMPs and national evidence-based guideline
implementation for type 2 diabetes in Germany. There
are several limitations to this study. First, we cannot
exclude selection bias, as persons who are severely ill,
hospitalized, or institutionalized were not included.
Therefore, our results may depict an overly optimistic
picture of diabetes quality of care both cross-sectionally
and over time. Second, diabetes diagnosis was self-
reported and not verified by medical records as occurs
in studies using patient registers. However, self-reported
physician-diagnosed diabetes provides a valid and inter-
nationally established indicator7 34 44 which permits
comparisons between countries as well as over time.
Third, information on gestational diabetes was collected
in DEGS17 but not in GNHIES98. Inclusion of women
with gestational diabetes may have reduced the survey-
specific rates of persons with diabetes who received
pharmacological treatment or preventive eye and foot
examinations in this study. Fourth, although data collec-
tion methods were kept comparable between surveys as
far as possible, changes to analytical methods for physio-
logical measurements remain a challenge to population-
based monitoring of BP and biomarkers.18 34 Finally, this
analysis was limited to intermediate outcome and
process indicators of diabetes care available in both
surveys. In particular, process of care indicators reflect-
ing self-management and patient education were limited
to glucose self-monitoring and holding a diabetes pass-
port in this study.
CONCLUSIONS
In conclusion, many diabetes quality of care indicators
have significantly improved over time from 1997–1999 to
2008–2011 in Germany, but a substantial proportion
of adults with diabetes do not achieve guideline-recom-
mended targets, particularly around lifestyle interven-
tions such as smoking cessation, weight reduction, and
physical activity similar to other international data.
Surveillance of national-level diabetes quality indicators
is required to evaluate the effects of changes in inter-
national guideline updates, national diabetes healthcare
policy, and changes to care management. Social inequal-
ities and regional variations in diabetes epidemiology
and diabetes quality of care need to be a central focus
of national surveillance activities. Most of all, the data-
base regarding subjective quality of care as well as long-
8 BMJ Open Diabetes Research and Care 2015;3:e000135. doi:10.1136/bmjdrc-2015-000135
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term outcomes and diabetes-related complications
needs to be strengthened.
Author affiliations
1Department of Epidemiology and Health Monitoring, Robert Koch Institute,
Berlin, Germany
2King’s College London, Faculty of Life Sciences and Medicine, London, UK
3Jean Philippe Assal Group for Health Services Research and Health
Economics, German Diabetes Center, Düsseldorf, Germany
4Public Health Unit, Faculty of Medicine, Heinrich-Heine University,
Düsseldorf, Germany
5German Centre for Diabetes Research (DZD), Munich, Germany
Contributors YD helped conceptionalize the study, performed the statistical
analyses, and drafted the manuscript. CH helped conceptionalize the study,
reviewed and edited the manuscript, and contributed to the discussion. ASR
performed the statistical modeling and contributed to the discussion. AB
reviewed and edited the manuscript and contributed to the discussion. RP,
HN, and AI reviewed the manuscript and contributed to the discussion. TR
was in charge of laboratory measurement quality control and reviewed the
manuscript. CSN conceptualized and supervised the study and substantially
contributed to the writing of the manuscript. CSN is the guarantor who takes
full responsibility for the work as a whole, including the study design, access
to data, and the decision to submit and publish the manuscript. All authors
read and approved the final version of the manuscript.
Funding National Health Surveys are funded by the Federal Ministry of Health
Germany (BMG) as part of the continuous national health monitoring. YD was
supported by a research grant from the Kompetenznetz Diabetes mellitus
(Competence Network Diabetes mellitus) funded by the Federal Ministry of
Education and Research (FKZ 01GI1110F).
Competing interests None declared.
Patient consent Obtained.
Ethics approval Charité Universitätsmedizin Berlin ethics committee.
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement No additional data are available specific to type 2
diabetes care among adults in Germany. For the DEGS survey system,
additional data are available for research collaborations as described in the
DEGS study protocol. http://www.biomedcentral.com/1471-2458/12/730
Open Access This is an Open Access article distributed in accordance with
the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license,
which permits others to distribute, remix, adapt, build upon this work non-
commercially, and license their derivative works on different terms, provided
the original work is properly cited and the use is non-commercial. See: http://
creativecommons.org/licenses/by-nc/4.0/
REFERENCES
1. OECD. Cardiovascular disease and diabetes: policies for better
health and quality of care, OECD health policy studies. Paris: OECD
Publishing, 2015.
2. World Health Organization (WHO). Global action plan for the
prevention and control of noncommunicable diseases 2013–2020.
2013. http://apps.who.int/iris/bitstream/10665/94384/1/
9789241506236_eng.pdf?ua=1
3. American Diabetes Association. Standards of medical care in
diabetes—2015. Diabetes Care 2015;38:S1–93.
4. Inzucchi S, Bergenstal R, Buse J, et al. Management of
hyperglycemia in type 2 diabetes: a patient-centered approach:
position statement of the American Diabetes Association (ADA) and
the European Association for the Study of Diabetes (EASD).
Diabetes Care 2012;35:1364–79.
5. Rydén L, Grant PJ, Anker SD, et al. ESC Guidelines on diabetes,
pre-diabetes, and cardiovascular diseases developed in
collaboration with the EASD: the Task Force on diabetes,
pre-diabetes, and cardiovascular diseases of the European Society
of Cardiology (ESC) and developed in collaboration with the
European Association for the Study of Diabetes (EASD). Eur Heart J
2013;34:3035–87.
6. The German Medical Association (Bundesärztekammer, BÄK), the
National Association of Statutory Health Insurance Physicians
(Kassenärztliche Bundesvereinigung, KBV), and the Association of
the Scientific Medical Societies (Arbeitsgemeinschaft der
Wissenschaftlichen Medizinischen Fachgesellschaften, AWMF).
[German National Disease Management Guideline Type 2 Diabetes],
version 4, updated November 2014. http://www.leitlinien.de/mdb/
downloads/nvl/diabetes-mellitus/dm-therapie-1aufl-vers4-lang.pdf
7. Heidemann C, Du Y, Schubert I, et al. [Prevalence and temporal
trend of known diabetes mellitus: results of the German Health
Interview and Examination Survey for Adults (DEGS1)].
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz
2013;56:668–77.
8. Fuchs S, Henschke C, Blümel M, et al. Disease management
programs for type 2 diabetes in Germany: a systematic literature
review evaluating effectiveness. Dtsch Arztebl Int 2014;111:453–63.
9. Rothe U, Müller G, Schwarz PE, et al. Evaluation of a diabetes
management system based on practice guidelines, integrated care,
and continuous quality management in a Federal State of Germany:
a population-based approach to health care research. Diabetes Care
2008;31:863–8.
10. Berthold HK, Bestehorn KP, Jannowitz C, et al. Disease
management programs in type 2 diabetes: quality of care. Am J
Manag Care 2011;17:393–403.
11. Schunk M, Stark R, Reitmeir P, et al. [Improvements in type 2
diabetes care? Pooled analysis of survey data in southern Germany
(KORA) from 1999–2008]. Bundesgesundheitsblatt
Gesundheitsforschung Gesundheitsschutz 2011;54:1187–96.
12. Stark R, Schunk M, Meisinger C, et al. Medical care of type 2
diabetes in German disease management programmes:
a population-based evaluation. Diabetes Metab Res Rev
2011;27:383–91.
13. Bellach BM, Knopf H, Thefeld W. Der Bundes-Gesundheitssurvey
1997/98 [The German Health Survey. 1997/98]. Gesundheitswesen
1998;60(Suppl 2):S59–68.
14. Scheidt-Nave C, Kamtsiuris P, Gößwald A, et al. German health
interview and examination survey for adults (DEGS)—design,
objectives and implementation of the first data collection wave. BMC
Public Health 2012;12:730.
15. Kamtsiuris P, Lange M, Hoffmann R, et al. [The first wave of the
German Health Interview and Examination Survey for Adults
(DEGS1): sample design, response, weighting and
representativeness]. Bundesgesundheitsblatt Gesundheitsforschung
Gesundheitsschutz 2013;56:620–30.
16. Knopf H, Grams D. [Medication use of adults in Germany: results of
the German Health Interview and Examination Survey for Adults
(DEGS1)]. Bundesgesundheitsblatt Gesundheitsforschung
Gesundheitsschutz 2013;56:868–77.
17. Mensink GB, Schienkiewitz A, Haftenberger M, et al. [Overweight
and obesity in Germany: results of the German Health Interview and
Examination Survey for Adults (DEGS1)]. Bundesgesundheitsblatt
Gesundheitsforschung Gesundheitsschutz 2013;56:786–94.
18. Neuhauser HK, Ellert U, Thamm M, et al. Calibration of blood
pressure data after replacement of the standard mercury
sphygmomanometer by an oscillometric device and concurrent
change of cuffs. Blood Press Monit 2015;20:39–42.
19. Brauns H, Scherer S, Steinmann S. The CASMIN Educational
Classification in International Comparative Research. In:
Hoffmeyer-Zlotnik JHP, Wolf C, eds. Advances in cross-national
comparison. A European working book for demographic and socio-
economic variables. New York: Kluwer Academic, 2003, 221–44.
20. World Health Organization (WHO). Obesity: preventing and
managing the global epidemic. WHO Technical Report Series 894,
Geneva, 2000.
21. Ali MK, Bullard KM, Saaddine JB, et al. Achievement of goals in U.
S. diabetes care, 1999–2010. N Engl J Med 2013;368:1613–24.
22. Stevens RJ, Kothari V, Adler AI, et al. The UKPDS risk engine: a
model for the risk of coronary heart disease in Type II diabetes
(UKPDS 56). Clin Sci (Lond) 2001;101:671–9.
23. Stevens PE, Levin A. Evaluation and management of chronic kidney
disease: synopsis of the kidney disease: improving global outcomes
2012 clinical practice guideline. Ann Intern Med 2013;158:825–30.
24. Levey AS, Stevens LA, Schmid CH, et al., CKD-EPI (Chronic Kidney
Disease Epidemiology Collaboration). A new equation to estimate
glomerular filtration rate. Ann Intern Med 2009;150:604–12.
25. Parikh CR, Fischer MJ, Estacio R, et al. Rapid microalbuminuria
screening in type 2 diabetes mellitus: simplified approach with Micral
test strips and specific gravity. Nephrol Dial Transplant
2004;19:1881–5.
BMJ Open Diabetes Research and Care 2015;3:e000135. doi:10.1136/bmjdrc-2015-000135 9
Epidemiology/health services research
  
26. Greenland S. Model-based estimation of relative risks and other
epidemiologic measures in studies of common outcomes and in
case-control studies. Am J Epidemiol 2004;160:301–5.
27. Szecsenyi J, Rosemann T, Joos S, et al. German diabetes disease
management programs are appropriate for restructuring care
according to the chronic care model: an evaluation with the patient
assessment of chronic illness care instrument. Diabetes Care
2008;31:1150–4.
28. Stock S, Drabik A, Büscher G, et al. German diabetes management
programs improve quality of care and curb costs. Health Aff
(Millwood) 2010;29:2197–205.
29. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of
diabetes mellitus and its complications. Part 1: diagnosis and
classification of diabetes mellitus provisional report of a WHO
consultation. Diabet Med 1998;15:539–53.
30. Geller JC, Cassens S, Brosz M, et al. Achievement of
guideline-defined treatment goals in primary care: the German
Coronary Risk Management (CoRiMa) study. Eur Heart J
2007;28:3051–8.
31. Genz J, Scheer M, Trautner C, et al. Reduced incidence of
blindness in relation to diabetes mellitus in southern Germany?
Diabet Med 2010;27:1138–43.
32. Icks A, Dickhaus T, Hörmann A, et al. Differences in trends in estimated
incidence of myocardial infarction in non-diabetic and diabetic people:
Monitoring Trends and Determinants on Cardiovascular Diseases
(MONICA)/Cooperative Health Research in the Region of Augsburg
(KORA) registry. Diabetologia 2009;52:1836–41.
33. Icks A, Haastert B, Trautner C, et al. Incidence of lower-limb
amputations in the diabetic compared to the non-diabetic population.
Findings from nationwide insurance data, Germany, 2005–2007. Exp
Clin Endocrinol Diabetes 2009;117:500–4.
34. Selvin E, Parrinello CM, Sacks DB, et al. Trends in prevalence and
control of diabetes in the United States, 1988–1994 and 1999–2010.
Ann Intern Med 2014;160:517–25.
35. Casagrande S, Fradkin JE, Saydah SH, et al. The prevalence of
meeting A1C, blood pressure, and LDL goals among people with
diabetes, 1988–2010. Diabetes Care 2013;36:2271–9.
36. Wong ND, Patao C, Wong K, et al. Trends in control of
cardiovascular risk factors among US adults with type 2 diabetes
from 1999 to 2010: Comparison by prevalent cardiovascular disease
status. Diab Vasc Dis Res 2013;10:505–13.
37. Ford ES. Trends in the control of risk factors for cardiovascular
disease among adults with diagnosed diabetes: findings from the
National Health and Nutrition Examination Survey 1999–2008.
J Diabetes 2011;3:337–47.
38. Kuznik A, Mardekian J. Trends in utilization of lipid- and blood
pressure-lowering agents and goal attainment among the U.S.
diabetic population, 1999–2008. Cardiovasc Diabetol
2011;10:31.
39. Gregg EW, Li Y, Wang J, et al. Changes in diabetes-related
complications in the United States, 1990–2010. N Eng J Med
2014;370:1514–23.
40. Braga MF, Casanova A, Teoh H, et al. Poor achievement of
guidelines-recommended targets in type 2 diabetes: findings from a
contemporary prospective cohort study. Int J Clin Pract
2012;66:457–64.
41. Navarro-Vidal B, Banegas JR, León-Muñoz LM, et al. Achievement
of cardiometabolic goals among diabetic patients in Spain.
A Nationwide Population-Based Study. PLoS ONE 2013;8.
42. Russell-Jones D, Khan R. Insulin-associated weight gain in diabetes
—causes, effects and coping strategies. Diabetes Obes Metab
2007;9:799–812.
43. Ross SA, Dzida G, Vora J, et al. Impact of weight gain on outcomes
in type 2 diabetes. Curr Med Res Opin 2011;27:1431–8.
44. Midthjell K, Holmen J, Bjorndal A, et al. Is questionnaire information
valid in the study of a chronic disease such as diabetes? The
Nord-Trondelag diabetes study. J Epidemiol Community Health
1992;46:537–42.




−1999 and 2008−xamination Surveys 1997
from German National Health Interview and E
Changes in diabetes care indicators: findings
Icks and Christa Scheidt-Nave
Buttery, Rebecca Paprott, Hannelore Neuhauser, Thea Riedel, Andrea 
Yong Du, Christin Heidemann, Angelika Schaffrath Rosario, Amanda
doi: 10.1136/bmjdrc-2015-000135
2015 3: BMJ Open Diab Res Care 
 http://drc.bmj.com/content/3/1/e000135





Supplementary material can be found at: 
References
 #BIBLhttp://drc.bmj.com/content/3/1/e000135
This article cites 38 articles, 12 of which you can access for free at: 
Open Access
http://creativecommons.org/licenses/by-nc/4.0/non-commercial. See: 
provided the original work is properly cited and the use is
non-commercially, and license their derivative works on different terms, 
permits others to distribute, remix, adapt, build upon this work
Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
This is an Open Access article distributed in accordance with the Creative
service
Email alerting
box at the top right corner of the online article. 
Receive free email alerts when new articles cite this article. Sign up in the
Collections
Topic Articles on similar topics can be found in the following collections 
 (29)Epidemiology/health services research
Notes
http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
http://journals.bmj.com/cgi/reprintform
To order reprints go to:
http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
